Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies ...

Earlier this week, Krystal Biotech reported positive interim data from the highest-dose cohort of its Phase 1 CORAL-1 trial, ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

For couples struggling with infertility, a genetic diagnosis can reduce years of repeated and inconclusive testing, guide ...

Protein–protein interaction networks are the networks of protein complexes formed by biochemical events and/or electrostatic forces and that serve a distinct biological function as a complex. The ...

Protein design (or protein engineering) is a technique by which proteins with enhanced or novel functional properties are created. Proteins can be engineered by rational design, which typically uses ...